http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma
-
Data on Tumor Treating Fields to Be Presented at American Association for Cancer Research Annual Meeting
-
Novocure to Report First Quarter 2018 Financial Results
-
NCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newly Diagnosed Glioblastoma
-
Novocure Announces 35 Presentations on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2018
-
Novocure Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Company Update
-
Novocure Secures New $150 Million Non-Dilutive Term Loan Financing
-
JAMA Oncology Publishes EF-14 Pivotal Trial Analysis Showing Optune Plus Temozolomide Improved Survival without Negatively Influencing Health-Related Quality of Life Compared to Temozolomide Alone in
-
Novocure Announces Fourth Quarter and Full Year 2017 Operating Statistics and Preliminary Revenue
-
Novocure to Participate in 36th Annual J.P. Morgan Healthcare Conference
-
Novocure (NVCR) Reports Publication of Final Analysis of EF-14 Phase 3 Pivotal Trial of Optune Together with Temozolomide Demonstrating Unprecedented Survival Results in JAMA
-
JAMA Publishes Final Analysis of EF-14 Phase 3 Pivotal Trial of Optune® Together with Temozolomide Demonstrating Unprecedented Survival Results for Newly Diagnosed Glioblastoma
-
Novocure (NVCR) Granted FDA IDE Approval for 3 Phase 3 Trials of PANOVA in Advanced Pancreatic Cancer
-
Novocure Receives FDA IDE Approval for its PANOVA 3 Phase 3 Pivotal Clinical Trial in Advanced Pancreatic Cancer
-
Novocure (NVCR) Announces Reimbursement Approval for Optune in Japan for Treatment of Newly Diagnosed GBM
-
Novocure Receives Reimbursement Approval for Optune® in Japan for the Treatment of Newly Diagnosed Glioblastoma
-
Novocure to Present at Two Upcoming Investor Conferences in December
-
Novocure (NVCR) Says Patients Who Used Optune More Than 90% of Time Had Greatest Chance of Survival in its EF-14 Trial
-
Patients Who Used Optune® More Than 90 Percent of the Time Had the Greatest Chance of Survival in Novocure’s EF-14 Trial: A Median Survival of 24.9 Months from Randomization and a Five-Year Surviva
-
Novocure Announces 28 Presentations on Tumor Treating Fields from Externally Led Clinical Research and Analysis at 22nd Annual Meeting of the Society for Neuro-Oncology
-
Novocure Announces 10 Presentations on Simulation Studies Aiming to Optimize Treatment Delivery of Tumor Treating Fields at 22nd Annual Meeting of the Society for Neuro-Oncology
-
Novocure Announces 13 Preclinical Presentations Highlighting Data on Tumor Treating Fields’ Mechanism of Action at 22nd Annual Meeting of the Society for Neuro-Oncology
-
Novocure Announces Six Clinical Presentations on Novocure’s Phase 3 Pivotal EF-14 Trial Data in Newly Diagnosed Glioblastoma at 22nd Annual Meeting of the Society for Neuro-Oncology
-
Novocure Reports Third Quarter 2017 Financial Results and Provides Company Update
-
Novocure Announces Data Presentations at the IASLC 18th World Conference on Lung Cancer
-
Novocure to Report Third Quarter 2017 Financial Results
-
Novocure (NVCR) Reports Data from Phase 3 Pivotal EF-14 Trial on Combination of Optune with Temozolomide
-
Combination of Optune® with Temozolomide Demonstrates Unprecedented Five-Year Survival for Newly Diagnosed Glioblastoma Patients
-
Novocure Announces Data Presentations at the American Society for Radiation Oncology’s 2017 Annual Meeting
-
Novocure (NVCR) Announces Data Presentations at ESMO
-
Novocure Announces Data Presentations at the ESMO 2017 Congress
-
Novocure (NVCR) Announces Support from German Federal Joint Committee for Clinical Trial to Study Optune
-
German Federal Joint Committee Announces Decision to Support a Clinical Trial to Study Optune® for the Treatment of Newly Diagnosed Glioblastoma
-
Novocure to Present at Two Upcoming Investor Conferences in September
-
Novocure™ Announces National Reimbursement for Optune® in Austria
-
Novocure to Present at the 2017 Wedbush PacGrow Healthcare Conference
-
Novocure Reports Second Quarter 2017 Financial Results and Provides Company Update
-
Novocure (NVCR) Reports Phase 1b Clinical Trial to Evaluate Safety of Marizomib and Temozolomide in Combination with Optune
-
Novocure™ Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide in Combination with Optune® as Adjuvant Therapy in Patients with Glioblastoma
-
Novocure’s Optune® Now Available at More Than 600 Cancer Treatment Centers in the U.S.
-
Data on Delivery of Tumor Treating Fields to be Presented at the 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society
-
Novocure to Report Second Quarter 2017 Financial Results
-
Novocure (NVCR) to Present Three Abstracts on Tumor Treating Fields and Pancreatic Cancer at ESMO
-
Novocure to Present Three Abstracts on Tumor Treating Fields and Pancreatic Cancer at the European Society for Medical Oncology 19th World Congress on Gastrointestinal Cancer
-
Novocure Announces Change to Presentation Time at the JMP Securities 2017 Life Sciences Conference
-
Novocure (NVCR) Says First Patient Enrolled in RTOG Trial of Optune with Bevacizumab for Patients with GBM
-
First Patient Enrolled in RTOG Trial of Optune® together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma
-
Health Care Service Corporation Issues Positive Coverage Decision for Optune
-
Novocure to Present at the JMP Securities 2017 Life Sciences Conference
-
Novocure™ Receives Humanitarian Use Device Designation for Treatment of Pleural Mesothelioma
